Fabino Life Sciences Limited

543444

INE0DRT01018

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:57 02/07/2024 BST			5-day change	1st Jan Change
27.35 ^INR	+4.99%		+0.37%	-0.55%

06-20	Fabino Life Sciences Changes Name to Fabino Enterprises	MT
05-28	Fabino Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Fabino Life Sciences Limited has filed an IPO.

November 26, 2021 at 05:00 am

Fabino Life Sciences Limited has filed an IPO.

Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 426,000

Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 474,000

Transaction Features: Regulation S

Latest news about Fabino Life Sciences Limited

Fabino Life Sciences Changes Name to Fabino Enterprises	06-20	MT
Fabino Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-28	CI
Fabino Life Sciences Limited Approves Executive Changes	12-26	CI
Fabino Life Sciences Limited Approves Change in Designation of Aditya Mahavir Jain from Non?Executive Director to Managing Director	12-26	CI
Fabino Life Sciences Managing Director Steps Down	12-26	MT
Fabino Life Sciences Limited Reports Earnings Results for the Half Year Ended September 30, 2023	11-13	CI
Fabino Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2023	18/08/23	CI
Fabino Life Sciences Limited Announces Incorporation of Wholly Owned Subsidiary	31/07/23	CI
Fabino Life Sciences Limited Announces Change in Registered Office Address	29/07/23	CI
Fabino Life Sciences Limited Announces Executive Changes	02/05/23	CI
Fabino Life Sciences Limited Announces Resignation of Aslam Mohammad as Company Secretary and Compliance Officer	25/04/23	CI
774,000 Equity Shares of Fabino Life Sciences Limited are subject to a Lock-Up Agreement Ending on 2-FEB-2023.	01/02/23	CI
Fabino Life Sciences Turns to Profit in Fiscal H1; Shares Jump 6%	24/11/22	MT
Fabino Life Sciences Limited Reports Earnings Results for the Half Year Ended September 30, 2022	09/11/22	CI
Fabino Life Sciences Limited Appoints Aslam Mohamrnad as Company Secretary and Compliance Officer	12/08/22	CI
Fabino Life Sciences Limited Announces Resignation of Jeel Poshiya as Company Secretary and Compliance Officer, Effective August 04, 2022	04/08/22	CI
Fabino Life Sciences Limited Announces Shifting of Registered Office	02/07/22	CI
Fabino Life Sciences Limited Appoints Sumit Malik as Additional Director (Non-Executive)	24/05/22	CI
Fabino Life Sciences Limited has completed an IPO in the amount of INR 32.4 million.	10/01/22	CI
Fabino Life Sciences Limited has filed an IPO.	26/11/21	CI

Chart Fabino Life Sciences Limited

Duration

Period

More charts

Company Profile

Fabino Enterprises Limited, formerly Fabino Life Sciences Ltd, is an India-based pharmaceutical company. It offers a range of allopathic and herbal products. Its product categories include allopathic products, Covid-19 products, food supplements, herbal products, multi-vitamin products, and veterinary products. Its allopathic products include AMOXRAG-625, Astrid Syrup, Aurceta AM, Aurifox OZ, Aurirug 200, Aurirug O, Aurnim Plus, Aurstin 250, Ceporag O, Doref M, Dr-DSR, F Plexus A, and Fabpara. Its Covid-19 products include disposable face shield, fabclean hand sanitizer, mask and personal protective equipment (PPE). Its herbal products include Aurcis-Forte, Aurzyme-Syrup, Ayush Kadha, Coptec-syrup, DStoren-Syrup, Ecstasy Tilla Oil, Fablactin, Giloy Power, Keepshine Hair Oil, Onion Hair Oil, Pain-Go, Power Malt, Regaliv-ds, Sandy Forte and M-Sharp-Brain-tonic. Its multi-vitamin products include Aur D3 Capsules, Coptec Capsules, FABZYM CAPSULE, Oshnine Plus, and Rigovit Softgel Capsules.

Sector

Pharmaceuticals

Calendar

05/11/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FABINO LIFE SCIENCES LIMITED	-0.55%	655K
ELI LILLY AND COMPANY	+55.55%	823B
NOVO NORDISK A/S	+42.31%	641B
JOHNSON & JOHNSON	-6.83%	352B
MERCK & CO., INC.	+17.15%	324B
ABBVIE INC.	+7.09%	301B
ASTRAZENECA PLC	+14.02%	241B
ROCHE HOLDING AG	+1.64%	223B
NOVARTIS AG	+13.66%	218B
AMGEN INC.	+7.87%	167B